Managers / Q1 2023 · view latest →
Repertoire Partners LP
CIK 0001909393 · 31 HUDSON YARDS, 11TH FLOOR SUITE #43, NEW YORK, NY, 10001 · 415-677-7050
Summary
Repertoire Partners LP reported $347M in U.S.-listed holdings across 32 positions for Q1 2023.
The portfolio is heavily concentrated: Ishares Tr alone accounts for 37.2% of reported value.
Compared with Q4 2022, the fund opened 10 new positions and exited 27.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 52.2% · $181M
- ETP · 37.2% · $129M
- Other · 9.2% · $32M
- US DOMESTIC · 1.4% · $5M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ISHARES TR | NEW | +723.5K | 723.5K | +$129M | $129M |
| BKIEURBLACK KNIGHT INC | NEW | +213.2K | 213.2K | +$12M | $12M |
| CMPCOMPASS MINERALS INTL INC | NEW | +50.0K | 50.0K | +$2M | $2M |
| ISHARES TR | NEW | +9.47M | 9.47M | +$2M | $2M |
| ETWOGBPE2OPEN PARENT HOLDINGS INC | NEW | +250.0K | 250.0K | +$1M | $1M |
| MIRMMIRUM PHARMACEUTICALS INC | NEW | +49.9K | 49.9K | +$1M | $1M |
| CUSHMAN WAKEFIELD PLC | NEW | +100.0K | 100.0K | +$1M | $1M |
| AQNALGONQUIN PWR UTILS CORP | NEW | +125.0K | 125.0K | +$1M | $1M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2023
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2025 | $143M | 10 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $227M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $252M | 16 | Feb 18, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $89M | 21 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $53M | 13 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $48M | 13 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $70M | 18 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $64M | 15 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $94M | 13 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $347M | 32 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $989M | 49 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $280M | 58 | Nov 23, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2022 | $300M | 90 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $1.5B | 57 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $121M | 36 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.